Important Concepts about First-Generation Antipsychotics

Jonathan M. Meyer; Stephen M. Stahl

doi:10.1017/9781009002103.009

6 - Important Concepts about First-Generation Antipsychotics

Published online by Cambridge University Press: 19 October 2021

Jonathan M. Meyer and

Stephen M. Stahl

Show author details

Jonathan M. Meyer: Affiliation:
University of California, San Diego
Stephen M. Stahl: Affiliation:
University of California, Riverside and San Diego

Book contents

Get access

Summary

First-generation antipsychotics (FGAs) have no unique therapeutic benefit compared to newer antipsychotics, but their utility derives from the fact that they are inexpensive, that multiple formulations exist including long-acting injectable (LAI) preparations, and that there is an extensive trove of plasma level studies for the more commonly used medications [1–5]. Large randomized trials such as the UK Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS-1) (n = 227) found that there was no disadvantage over 1 year of treatment in terms of quality of life, symptoms, or associated costs of care when using FGAs, compared to second-generation antipsychotics (SGAs) (clozapine excepted) [6].

Type: Chapter
Information: The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 147 - 156

DOI: https://doi.org/10.1017/9781009002103.009 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Van Putten, T., Marder, S. R., and Mintz, J. (1985). Plasma haloperidol levels: Clinical response and fancy mathematics. Arch Gen Psychiatry, 42, 835–838.Google Scholar

Van Putten, T., Marder, S. R., Wirshing, W. C., et al. (1991). Neuroleptic plasma levels. Schizophr Bull, 17, 197–216.Google Scholar

Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254–264.Google Scholar

de Oliveira, I. R., de Sena, E. P., Pereira, E. L., et al. (1996). Haloperidol blood levels and clinical outcome: A meta-analysis of studies relevant to testing the therapeutic window hypothesis. J Clin Pharm Ther, 21, 229–236.Google Scholar

Ulrich, S., Wurthmann, C., Brosz, M., et al. (1998). The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet, 34, 227–263.Google Scholar

Jones, P. B., Barnes, T. R. E., Davies, L., et al. (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, 63, 1079–1087.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: A joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.Google Scholar

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., et al. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet, 394, 939–951.Google Scholar

Pillinger, T., McCutcheon, R. A., Vano, L., et al. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. Lancet Psychiatry, 7, 64–77.Google Scholar

Kahn, R. S., Winter van Rossum, I., Leucht, S., et al. (2018). Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): A three-phase switching study. Lancet Psychiatry, 5, 797–807.Google Scholar

Meyer, J. M. and Stahl, S. M. (2019). The Clozapine Handbook. Cambridge: Cambridge University Press.Google Scholar

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 1209–1223.Google Scholar

Xiong, G. L., Pinkhasov, A., Mangal, J. P., et al. (2020). QTc monitoring in adults with medical and psychiatric comorbidities: Expert consensus from the Association of Medicine and Psychiatry. J Psychosom Res, 135, 110138.Google Scholar

Van Putten, T., Marder, S. R., Mintz, J., et al. (1992). Haloperidol plasma levels and clinical response: A therapeutic window relationship. Am J Psychiatry, 149, 500–505.Google Scholar

Salem, H., Nagpal, C., Pigott, T., et al. (2017). Revisiting antipsychotic-induced akathisia: Current issues and prospective challenges. Curr Neuropharmacol, 15, 789–798.Google Scholar

Vinogradov, S., Fisher, M., Warm, H., et al. (2009). The cognitive cost of anticholinergic burden: Decreased response to cognitive training in schizophrenia. Am J Psychiatry, 166, 1055–1062.Google Scholar

Ang, M. S., Abdul Rashid, N. A., Lam, M., et al. (2017). The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. J Clin Psychopharmacol, 37, 651–656.Google Scholar

Eum, S., Hill, S. K., Rubin, L. H., et al. (2017). Cognitive burden of anticholinergic medications in psychotic disorders. Schizophr Res, 190, 129–135.Google Scholar

Meyer, J. M. and Koro, C. E. (2004). The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophr Res, 70, 1–17.Google Scholar

Leucht, S., Crippa, A., Siafis, S., et al. (2020). Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry, 177, 342–353.Google Scholar

Schoretsanitis, G., Spina, E., Hiemke, C., et al. (2018). A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol, 11, 1237–1253.Google Scholar

de Leon, J., Wynn, G., and Sandson, N. B. (2010). The pharmacokinetics of paliperidone versus risperidone. Psychosomatics, 51, 80–88.Google Scholar

Covell, N. H., McEvoy, J. P., Schooler, N. R., et al. (2012). Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: An open-label, randomized controlled trial. J Clin Psychiatry, 73, 669–675.Google Scholar

Leucht, S., Samara, M., Heres, S., et al. (2016). Dose equivalents for antipsychotic drugs: The DDD method. Schizophr Bull, 42 Suppl 1, S90–94.Google Scholar

Asmal, L., Flegar, S. J., Wang, J., et al. (2013). Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, CD006625.Google Scholar

Vanasse, A., Blais, L., Courteau, J., et al. (2016). Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: A real-world observational study. Acta Psychiatr Scand, 134, 374–384.Google Scholar

Meyer, J. M., Davis, V. G., Goff, D. C., et al. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophr Res, 101, 273–286.Google Scholar

Meyer, J. M. (2010). Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci, 4, 23–42.Google Scholar

Regenthal, R., Kunstler, U., Junhold, U., et al. (1997). Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Int Clin Psychopharmacol, 12, 255–261.Google Scholar

Fitzgerald, P. B., Kapur, S., Remington, G., et al. (2000). Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology, 149, 1–5.Google Scholar

Nyberg, S., Farde, L., Bartfai, A., et al. (1995). Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol, 10, 221–227.Google Scholar

Lundbeck Australia (2013). Clopixol, Clopixol Acuphase, Clopixol Depot package insert. North Ryde, NSW, Australia.Google Scholar

Chang, W. H., Lin, S. K., Juang, D. J., et al. (1993). Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal. Schizophr Res, 9, 35–40.Google Scholar

Nyberg, S., Farde, L., and Halldin, C. (1996). Long-time persistence of D2 dopamine receptor occupancy after discontinuation of haloperidol decanoate. Schizophr Res, 18, 199–200.Google Scholar

Talvik, M., Nordstrom, A. L., Larsen, N. E., et al. (2004). A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology, 175, 148–153.Google Scholar

Ereshefsky, L., Toney, G., Saklad, S. R., et al. (1993). A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry, 44, 1155–1161.Google Scholar

Taylor, D. (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review. Br J Psychiatry Suppl, 52, S13–19.Google Scholar

Dencker, S. J., Giös, I., Mårtensson, E., et al. (1994). A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology (Berl), 114, 24–30.Google Scholar